Kang Donghoon, Park Jae Myung, Lee Sung Hak, Cho Yu Kyung, Lee Bo-In, Choi Myung-Gyu
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Korean J Helicobacter Up Gastrointest Res. 2023 Dec;23(4):283-293. doi: 10.7704/kjhugr.2023.0039. Epub 2023 Dec 8.
Adenosine triphosphate-binding cassette subfamily G member 2 (ABCG2) and CD133 are recognized stem cell markers of gastric cancer. Extensive research has examined the significance of these markers in different types of cancers and their impact on prognoses, linking them to unfavorable clinical outcomes in various tumors. However, the prognostic value of these markers for gastric cancer remains unclear. We investigated the expression of ABCG2 and CD133 and their relationship with clinical outcomes in gastric cancer.
ABCG2 and CD133 expression levels were analyzed, using immunohistochemistry and tissue microarrays, in tumor samples from 459 patients who underwent surgical resections due to gastric cancer. ABCG2 and CD133 expression levels were defined by intensity and dichotomized as medians. The associations among the expression levels of these markers, disease severity, and patient survival were also determined.
In the 411 patients for whom we analyzed the expression levels of these markers, 74.9% and 80.5% were found to have high levels of ABCG2 and CD133, respectively. High expression levels of ABCG2 and CD133 were more commonly observed in well-differentiated (<0.001 and =0.004, respectively) and intestinal lesions (<0.001 and =0.002, respectively). High ABCG2 expression correlated with improved survival outcomes, whereas high CD133 expression was associated with poorer outcomes. Cox regression analysis confirmed that stage, high ABCG2 (overall survival [OS]: hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.41-0.91; =0.015; recurrencefree survival [RFS]: HR, 0.55; 95% CI, 0.34-0.88; =0.012), and CD133 expression (OS: HR, 1.59; 95% CI, 1.00-2.51; =0.049; RFS: HR, 2.29; 95% CI, 1.21-4.34; =0.011) were predictors of survival. A subgroup analysis indicated that ABCG2 expression was also associated with an improved RFS rate in patients who received systemic chemotherapy.
High ABCG2 expression and low CD133 expression in tumors correlated with improved survival outcomes in post-resection patients with gastric cancer, suggesting their potential utility as prognostic biomarkers.
三磷酸腺苷结合盒亚家族G成员2(ABCG2)和CD133是公认的胃癌干细胞标志物。广泛的研究已探讨了这些标志物在不同类型癌症中的意义及其对预后的影响,发现它们与多种肿瘤的不良临床结局相关。然而,这些标志物对胃癌的预后价值仍不明确。我们研究了ABCG2和CD133的表达及其与胃癌临床结局的关系。
采用免疫组织化学和组织芯片分析了459例因胃癌接受手术切除患者的肿瘤样本中ABCG2和CD133的表达水平。ABCG2和CD133的表达水平根据强度进行定义,并以中位数进行二分法划分。还确定了这些标志物的表达水平、疾病严重程度和患者生存率之间的关联。
在我们分析了这些标志物表达水平的411例患者中,分别有74.9%和80.5%的患者ABCG2和CD133水平较高。ABCG2和CD133的高表达在高分化(分别为<0.001和=0.004)和肠型病变(分别为<0.001和=0.002)中更常见。ABCG2高表达与较好的生存结局相关,而CD133高表达与较差的结局相关。Cox回归分析证实,分期、ABCG2高表达(总生存期[OS]:风险比[HR],0.61;95%置信区间[CI],0.41 - 0.91;=0.015;无复发生存期[RFS]:HR,0.55;95% CI,0.34 - 0.88;=0.012)和CD133表达(OS:HR,1.59;95% CI,1.00 - 2.51;=0.049;RFS:HR,2.29;95% CI,1.21 - 4.34;=0.011)是生存的预测因素。亚组分析表明,ABCG2表达也与接受全身化疗患者的RFS率提高相关。
肿瘤中ABCG2高表达和CD133低表达与胃癌切除术后患者较好的生存结局相关,提示它们作为预后生物标志物的潜在效用。